$RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$3.20
▲+1.27%+$0.040
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateRecursion Pharmaceuticals, Inc. Class A Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is RXRX up today? It is at $3.20 (+1.27%), and our scanner flagged it 240 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment RXRX spikes, and full due diligence on RXRX — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $RXRX 240 times in the last 30 days. Create a free account to track $RXRX, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on RXRX from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for RXRX today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystRECURSION PHARMACEUTICALS, INC.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filing4Insider trade (Form 4)Sep 10, 2026 · 2 days agoAcross every filing on file, supply equal to 75.6% of the tradeable float is in play - 75.6% more can still be issued.
At-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing)
84,985,836 new shares · At-the-market (ATM) program — sells new shares into the market gradually over time · About $300.0M in size · Priced at $3.53/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Khan Najat Officer | Sold (automatic/other) | -22K | sold 1.1% | 2.07M | $79K at $3.52 | Sep 8, 26 |
Borgeson Blake Director | Sold (automatic/other) | -30K | sold 0.5% | 6.16M | $100K at $3.34 | Sep 1, 26 |
Taylor Ben R Officer | Sold (automatic/other) | -25K | sold 2.3% | 1.08M | $79K at $3.16 | Aug 17, 26 |
Hallett David Officer | Sold (automatic/other) | -27K | sold 2.5% | 1.04M | $84K at $3.16 | Aug 17, 26 |
Khan Najat Officer | Sold (automatic/other) | -80K 0.02% of company | sold 3.7% | 2.10M | $254K at $3.16 | Aug 17, 26 |
Borgeson Blake Director | Sold (automatic/other) | -30K | sold 0.5% | 6.19M | $98K at $3.25 | Aug 4, 26 |
Borgeson Blake Director | Sold (automatic/other) | -40K | sold 0.6% | 6.22M | $158K at $3.96 | Jul 7, 26 |
Li Dean Y Director | Acquired (grant/award) | +4K | added 0.3% | 1.47M | n/a | Jul 1, 26 |
Dar Zavain Director | Acquired (grant/award) | +5K | added 2.2% | 241K | n/a | Jul 1, 26 |
Bumpus Namandje Director | Sold (automatic/other) | -4K | sold 3.0% | 128K | $13K at $3.18 | Jun 18, 26 |
Li Dean Y Director | Acquired (grant/award) | +88K 0.02% of company | added 6.4% | 1.47M | n/a | Jun 17, 26 |
Bumpus Namandje Director | Acquired (grant/award) | +88K 0.02% of company | added 100% | 132K | n/a | Jun 17, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on RXRX from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for RXRX today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
RXRX last traded at $3.20, up 1.27% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) is next expected to report earnings on Wednesday, November 4, 2026, about 52 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The RXRX Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged RXRX 240 times in the last 30 days.
RXRX (Recursion Pharmaceuticals, Inc. Class A Common Stock) trades on XNAS, with a market cap of about $1.71B in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge RXRX for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$RXRX discussion
Sign in to ask a question or join the discussion.